MX9401331A - Composicion farmaceutica y articulo util para inhibir la irritacion de la piel. - Google Patents

Composicion farmaceutica y articulo util para inhibir la irritacion de la piel.

Info

Publication number
MX9401331A
MX9401331A MX9401331A MX9401331A MX9401331A MX 9401331 A MX9401331 A MX 9401331A MX 9401331 A MX9401331 A MX 9401331A MX 9401331 A MX9401331 A MX 9401331A MX 9401331 A MX9401331 A MX 9401331A
Authority
MX
Mexico
Prior art keywords
agent
drug delivery
transdermal drug
sensitizing
pharmaceutical composition
Prior art date
Application number
MX9401331A
Other languages
English (en)
Inventor
John Wille
Agis Kydonieus
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21807714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9401331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9401331A publication Critical patent/MX9401331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe métodos y composiciones para inhibir o evitar la irritación o efectos de sensibilización de la piel de un componente que irrita o sensibiliza de la piel de un sistema de suministro de una fármaco dérmico o transdérmico. La posición consiste de un agente de desgranulación de células cebadas, el cual es capaz de inducir un estado de tolerancia inmunológica al agente de sensibilización de la piel, por el suministro antes de o en el inicio del suministro del fármaco transdérmico. Tal agente, de preferencia el ácido cis-urocánico o un análogo o metabólico del mismo, puede administrarse, antes, durante o después de cada suministro del fármaco transdérmico, para lograr contra-sensibilización a la tolerancia inmune. Alternativamente, el agente puede ser utilizado para inducir la contra-sensibilización. El agente de preferencia es capaz de atravesar la epidermis y se administra transdérmicamente. También se describen métodos novedosos y composiciones que consisten del ácido cisurocánico o un análogo o metabólico del mismo para obtener los efectos anti-inflamatorios.
MX9401331A 1993-02-25 1994-02-22 Composicion farmaceutica y articulo util para inhibir la irritacion de la piel. MX9401331A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2208093A 1993-02-25 1993-02-25

Publications (1)

Publication Number Publication Date
MX9401331A true MX9401331A (es) 1994-08-31

Family

ID=21807714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9401331A MX9401331A (es) 1993-02-25 1994-02-22 Composicion farmaceutica y articulo util para inhibir la irritacion de la piel.

Country Status (8)

Country Link
EP (1) EP0612525B1 (es)
JP (1) JPH072670A (es)
AT (1) ATE205713T1 (es)
AU (1) AU686123B2 (es)
CA (1) CA2114968A1 (es)
DE (1) DE69428295T2 (es)
MX (1) MX9401331A (es)
ZA (1) ZA94856B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2719474B1 (fr) 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
US5672640A (en) * 1995-07-12 1997-09-30 Caschem, Inc. Polypropylene compatible grease compositions for optical fiber cable
WO1997004832A1 (en) * 1995-07-25 1997-02-13 Massachusetts Institute Of Technology Enhanced transdermal transport using ultrasound
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
FR2740040B1 (fr) * 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
WO1997047355A1 (en) * 1996-06-12 1997-12-18 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
JP2002515786A (ja) 1996-06-28 2002-05-28 ソントラ メディカル，エル．ピー． 経皮輸送の超音波増強
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US7812010B2 (en) * 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus
WO2004091521A2 (en) 2003-04-10 2004-10-28 Neurogesx, Inc. Methods and compositions for administration of trpv1 agonists
FI20031793A0 (fi) * 2003-12-09 2003-12-09 Lasse Leino Uusi anti-proliferatiivinen farmaseuttinen koostumus
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US20060094944A1 (en) 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis with error correction
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
JP4393552B2 (ja) * 2005-08-01 2010-01-06 マルホ株式会社 ピリドンカルボン酸誘導体を含有するローション剤
EP2124723A1 (en) 2007-03-07 2009-12-02 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
SI2152358T1 (sl) 2007-04-27 2011-08-31 Echo Therapeutics Inc Naprava za prodiranje skozi koĺ˝o za analizno merjenje ali za transdermalni prenos zdravil
JP5758587B2 (ja) * 2010-05-13 2015-08-05 智 堀越 ビニルイミダゾール類の光異性化方法
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
EP0467116B2 (de) * 1990-06-29 2001-12-05 Gs Development Ab Dermatologische Zusammensetzungen mit einem Gehalt an cis-Urocaninsäure
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices

Also Published As

Publication number Publication date
EP0612525B1 (en) 2001-09-19
ZA94856B (en) 1994-09-05
JPH072670A (ja) 1995-01-06
ATE205713T1 (de) 2001-10-15
EP0612525A1 (en) 1994-08-31
DE69428295T2 (de) 2002-06-20
DE69428295D1 (de) 2001-10-25
AU686123B2 (en) 1998-02-05
CA2114968A1 (en) 1994-08-26
AU5635094A (en) 1994-09-01

Similar Documents

Publication Publication Date Title
MX9401331A (es) Composicion farmaceutica y articulo util para inhibir la irritacion de la piel.
US5202125A (en) Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
EP0261429B1 (en) Penetration enhancement systems and the preparation thereof
US4696821A (en) Transdermal delivery system for administration of nitroglycerin
IE871981L (en) Programmed release formulation.
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
DK0610595T3 (da) Sammensætning af L-DOPA-estere
DK0535327T3 (da) Farmaceutisk præparat indeholdende felbinac
DK18089A (da) Galeniske praeparater med programmeret frigivelse
US4931283A (en) Menthol enhancement of transdermal drug delivery
JPS60152413A (ja) メントールにより経皮性薬剤放出の強化を行なつた局所用組成物
SE8001599L (sv) Transdermalt medicineringssystem for isosorbiddinitrat
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
EP0584126B1 (de) Lanolinderivate als penetrationsfördernde substanzen
US20160184331A1 (en) Base and external preparation for skin
US4923875A (en) Method for treatment of mast cell-mediated dermatologic disorders
JP3040427B2 (ja) 神経痛治療用アスピリン含有軟膏組成物
US5449670A (en) Composition and method for the transdermal delivery of bioactive peptides
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
KR880002506A (ko) 경피성 조성물
EP0188538B1 (en) Transdermal delivery of azatadine
US20070065496A1 (en) Dermal therapeutic system comprising 2-(3-benzophenyl)propionic acid
US4873266A (en) Menthone enhancement of transdermal drug delivery
EP0397211B1 (en) Percutaneous administration of 3'-azide-3'-deoxythymidine
EP1043979B1 (en) Compositions for the transdermal and dermal administration of biologically active agents

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees